Two Pathways to Living Bone: Why Graft Processing Determines Fate
You’re choosing grafts by brand name. You should be choosing by biological programme.
The Promise Every Graft Makes
Every bone graft material makes the same promise: fill the defect, support healing, enable implant placement.
But not all grafts keep that promise the same way.
Some maintain volume by persisting as a permanent scaffold — the particles are still there years later, embedded in fibrous tissue. Others maintain volume temporarily while being completely transformed into living bone that remodels and integrates like native tissue.
The difference? It’s not the brand name. It’s not the marketing. It’s not even the species.
It’s whether the processing preserved the biological conditions that allow osteoclasts to do their job — attach, resorb, and replace graft with living bone.
There are two distinct mechanisms that enable this. And one processing approach that prevents it entirely.
Understanding this framework changes how you select materials. And once you understand it, you can’t go back to choosing grafts based on what the rep recommends.
The Two Pathways to Biological Turnover
For a graft material to be replaced by living bone, osteoclasts must be able to attach to it, resorb it, and initiate coupled remodelling — the same process that maintains your skeleton throughout life. There are two ways processing can preserve this capacity.
Pathway 1: Collagen-Mediated Turnover
Processing: Low temperature, below 130 degrees C, with collagen matrix preserved.
How it works: The preserved collagen contains RGD (arginine-glycine-aspartic acid) sequences — the molecular addresses that cells recognise as “this is bone matrix.” When macrophages encounter these sequences, integrin receptor binding occurs, triggering a signalling cascade that favours M2 polarisation. M2 macrophages drive regeneration rather than inflammation. Osteoclasts can attach to the collagen, resorb the material, and replace it with new bone through coupled remodelling.
The biological cascade:
RGD sequences intact –> integrin receptor binding –> M2 macrophage polarisation –> osteoclast attachment –> coupled remodelling –> vital bone replacement
What you get: A material that participates in biology. The graft doesn’t just sit there — it is actively recognised, resorbed, and replaced. Over 12-24 months, the graft particles disappear and living bone takes their place.
Examples: Dual-phase collagenated porcine xenografts (GTO, MP3) where the collagen matrix is deliberately preserved through low-temperature processing.
Pathway 2: Porosity-Mediated Turnover
Processing: Low temperature (130 degrees C), with all organic content removed — but native bone architecture preserved.
How it works: This is where it gets interesting, and where most courses get it wrong. Some materials remove all collagen and organic content — technically making them “deproteinised” — but because the processing temperature is low enough to avoid sintering, the native crystal structure, interconnected pore network, and surface characteristics of the original bone are preserved.
The key metric is porosity. When total porosity exceeds 75% with preserved macro-, micro-, and nanopore interconnectivity, the material provides a three-dimensional highway for fluid uptake, cell migration, and vascular invasion. The low crystallinity (because the hydroxyapatite was never sintered at extreme temperatures) means osteoclasts can engage and resorb the mineral. The interconnected pore system ensures blood reaches every part of the scaffold.
The biological cascade:
Native pore architecture preserved –> high porosity (greater than 75%) + interconnectivity –> rapid fluid uptake and cell migration –> low crystallinity enables osteoclastic resorption –> coupled remodelling –> vital bone replacement
What you get: A material that achieves the same endpoint as collagen-mediated turnover — active resorption and replacement by living bone — through a completely different mechanism. Instead of molecular recognition via RGD sequences, the turnover is driven by architectural fidelity. The material resorbs because its physical structure invites osteoclastic engagement, not because collagen tells cells what to do.
The evidence: Physicochemical characterisation shows porosity of 78.4% with a specific surface area of 69.9 m2/g — dramatically higher than high-temperature sintered bovine materials (62% porosity, 0.5 m2/g). In sinus augmentation, residual graft particles measured only 11.9% at 6 months and dropped to 6.1% by 12 months, while new bone formation rose from 18.9% to 40.2% over the same period. Histology confirms TRAP-positive multinucleated giant cells actively degrading the material. In head-to-head RCTs against sintered bovine xenograft, the porcine material showed comparable new bone formation but with smaller residual particles at the same timepoint — confirming faster turnover.
Examples: Deproteinised porcine bone mineral processed at low temperature with preserved native architecture (THE Graft, Purgo Biologics).
The Third Category: Structural Persistence
High-Temperature Processing (Anorganic/Sintered)
Processing: Exceeding 300 degrees C, typically 1000 degrees C or higher.
What this does: At these temperatures, everything biological is destroyed. Collagen is incinerated. But more importantly, the hydroxyapatite crystals undergo sintering — they fuse together, dramatically increasing crystallinity and reducing porosity. The native bone architecture is fundamentally altered. What remains is a dense, highly crystalline mineral scaffold.
Why it fails biologically:
RGD sequences destroyed –> no integrin signalling –> M1 macrophage persistence –> osteoclast attachment impaired –> minimal resorption –> permanent particle persistence
The high crystallinity means osteoclasts struggle to dissolve the mineral. The reduced porosity means blood vessels can’t penetrate efficiently. The material persists as particles embedded in fibrous tissue — histology at 11 years shows them “largely unchanged.”
What you get: A scaffold. It holds space. It provides structure. But it does not transform into bone. Volume is maintained through persistence, not through biological turnover.
Examples: Bio-Oss, Cerabone, and other high-temperature sintered bovine bone minerals (DBBM).
Same Endpoint, Two Mechanisms — One Paradigm
Here’s the insight that changes material selection: the Academy doesn’t prefer collagenated materials because of collagen per se. We prefer materials that undergo biological turnover — that get replaced by living, vital bone.
Collagen is one mechanism to achieve that. Preserved native porosity is another.
The discriminator isn’t “does it contain collagen?” It’s “does it get replaced by living bone?”
Both collagen-mediated and porosity-mediated materials achieve this. High-temperature sintered materials do not.
This is why processing matters more than brand name, more than species origin, and more than what your rep told you over lunch. Two materials can both be porcine-derived, both xenogeneic, both “bone graft” — and have completely different biological programmes based on how they were processed.
Histological Timelines: What Actually Happens Over Time
At 6 Months:
Sintered materials (structural persistence): Particles persistent with minimal remodelling. Surrounded by fibrous tissue. Structurally present but biologically inert.
Collagenated and high-porosity materials (biological turnover): Active resorption visible. New bone formation throughout. Dynamic remodelling in progress. In porosity-mediated materials, residual graft already below 12%.
At 12 Months:
Sintered materials: Particles still persistent. Composite tissue — part graft, part fibrous tissue, minimal vital bone. The material is still there.
Collagenated and high-porosity materials: Significant replacement with vital bone. Material being transformed, not just encapsulated. In porosity-mediated materials, residual graft below 6% with new bone exceeding 40%. Trabecular architecture developing.
Long-Term (Years):
Sintered materials: Particles remaining “largely unchanged” even at 11 years. Permanent scaffold embedded in tissue. Volume maintained, but not through bone.
Collagenated and high-porosity materials: Complete turnover potential. Native bone quality. Indistinguishable from natural bone remodelling.
One material maintains volume through persistence. The other maintains volume through transformation.
Which biological programme do you want in your patient’s jaw?
The Regenerative Hierarchy: What to Use When
Understanding the processing-behaviour paradigm gives you a framework for material selection based on biology, not marketing.
Priority 1: Autogenous Bone (Gold Standard)
When to use: Complex defects. Compromised healing (diabetic, smoker, radiation). Maximum biological requirement.
Why it works: Living cells, intact growth factors, complete biological signalling. Nothing beats it for regenerative potential.
Priority 2: Autogenous Plus Biological Turnover Xenograft
When to use: Volume extension beyond what you can harvest. Standard augmentation where you need both biology and volume.
Why it works: Autogenous provides the cellular biology. Collagenated or high-porosity xenograft extends the volume while maintaining the regenerative programme. Both pathways support this combination.
Priority 3: Biological Turnover Xenograft Alone
When to use: Socket preservation. Small to moderate defects. Good host biology.
Why it works: Whether collagen-mediated (preserved RGD sequences supporting M2 polarisation and osteoclast attachment) or porosity-mediated (native architecture enabling osteoclastic resorption through interconnected pore networks), these materials achieve active biological turnover. The graft becomes native bone.
Priority 4: Sintered Xenograft (Not Recommended)
When it’s used: When clinicians don’t understand the processing-behaviour paradigm.
What it achieves: Structural success without biological success. Volume maintained through particle persistence, not bone formation.
The problem: You’re choosing a permanent scaffold when you could choose a transformative material.
The Two Questions You Need to Ask
Material selection is not about brand names. It’s about understanding the biological programme your material delivers.
So here are the two questions:
Question 1: What is the processing temperature?
Below 130 degrees C preserves the conditions for biological turnover — either through collagen retention or through architectural preservation. Above 300 degrees C destroys both pathways and commits you to structural persistence.
Question 2: What is the total porosity?
Above 75% with interconnected macro-, micro-, and nanopores enables rapid vascularisation, cell migration, and osteoclastic engagement — even without collagen. Below 65% (typical of sintered materials) limits biological access and favours persistence.
Those two numbers — temperature and porosity — tell you more about biological behaviour than any brochure, any brand name, or any sales presentation.
At the Academy of Implant Excellence, we teach the biology behind the protocols. Understanding why processing determines graft fate — and that there are two distinct biological pathways to living bone — is one example of the depth that changes material selection. Not because it’s complicated, but because most courses teach “use this brand for sinus lifts” without explaining the biology that determines whether your graft persists or transforms.
And once you understand that biological turnover is the goal, and that both collagen and porosity can get you there, you can’t go back to choosing materials based on which rep bought you lunch.
Ready to Understand the Biology Behind the Protocols?
The Academy of Implant Excellence teaches system-agnostic, biology-first implant training. From single implants to full-arch mastery. 80+ hours of depth that covers the invisible 10% where complications happen.
Because protocols work until they don’t.
References
Khaira P. Dual-Phase Xenograft Processing Review. Academy of Implant Excellence, 2025.
Lee JH, Yi GS, Lee JW and Kim DJ. Physicochemical characterization of porcine bone-derived grafting material and comparison with bovine xenografts for dental applications. Journal of Periodontal and Implant Science, 2017; 47(6): 388-401.
Soardi CM, Cavani F, Soardi B, Zaffe D and Wang HL. Maxillary sinus floor augmentation with porcine-apatite xenograft: a prospective case series study. International Journal of Periodontics and Restorative Dentistry, 2023; 43(6): 687-697.
Lee JS, Shin HK, Yun JH and Cho KS. Randomized clinical trial of maxillary sinus grafting using deproteinized porcine and bovine bone mineral. Clinical Implant Dentistry and Related Research, 2016; 19(1): 140-150.
Wang X, Cui F et al. Mineralized Collagen Bone Graft Substitutes. Beijing Allgens Medical, 2019.
Khoury F et al. Autogenous Bone Harvesting and Grafting. Quintessence, 2022.